Navegando por Palavras-chave "Ovarian Cancer"

Agora exibindo 1 - 2 de 2
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Correlação entre os genes p53 e HIF-1-Alfa por técnica de imuno-histoquímica para avaliar os tumores de mulheres com câncer de ovário que obtiveram resposta positiva ou negativa ao tratamento com quimioterapia
    (Universidade Federal de São Paulo (UNIFESP), 2020-03-05) Escani, Juliana Cahale [UNIFESP]; Rocha, Rafael Malagoli [UNIFESP]; http://lattes.cnpq.br/0319099107474192; http://lattes.cnpq.br/2938366458915364; Universidade Federal de São Paulo
    Introduction: Ovarian cancer is considered one of the most lethal gynecological cancers for women. This cancer has four stages and can originate from different cell types. There are some factors that can lead to a higher risk of ovarian cancer such as family history, age and obesity. In contrast, there are some preventive factors for this cancer like a diet rich in healthy foods and physical activity. The absence of specific symptoms of this cancer leads to a delay in diagnosis, causing, in most cases, a late diagnosis of the cancer at a more advanced stage. Some tumor markers are related to ovarian cancer, such as p53 antibody. Objective: This study was intended to evaluate the correlation between immunohistochemical results of p53 antibody with clinical, demographic and anatomopathological data of the patients. Methods: A TMA (Tissue Microarray) was constructed with samples from 138 patients with high-grade serous epithelial ovarian cancer with stage III for analysis of the antibody. P53 antibody have been previously validated by immunohistochemistry. After validation, immunohistochemical was used to analyze the p53 protein in the TMA slide. Results: Results were statistically analyzed. The average age of patients diagnosed with ovarian cancer was 59 years. From 103 patients of the final p53 analysis, 70 patients were treatment sensitive and 26 patients were resistant. Only 10 patients had blood vascular invasion. Conclusion: The immunohistochemical results for the p53 antibody were directly related to age, sensitivity to adjuvant chemotherapy, relapse, death, mitosis in 10 fields and disease-free survival. Besides that, some clinical aspects were related to each other, such as, patients resistant to adjuvant chemotherapy presented high amount of mitoses in 10 fields.
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Epidemiologia e os desfechos clínicos de pacientes com carcinoma de pequenas células do ovário, tipo hipercalcêmico (SCCOHT)
    (Universidade Federal de São Paulo (UNIFESP), 2020-11-26) Callegaro Filho, Donato [UNIFESP]; Speck, Neila Maria De Gois [UNIFESP]; Universidade Federal de São Paulo
    Objective: Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT) is a rare disease with a poor prognosis. SCCOHT has recently been shown to be associated with SMARCA4 gene mutations as well as molecular and genetic similarities to malignant rhabdoid tumors (MRT). The objective of our study is to describe the clinical characteristics, treatment modalities and outcomes of patients with SCCOHT. Methods: We performed a retrospective analysis of 47 patients with SCCOHT evaluated at MD Anderson Cancer Center between 1990 and 2014. Medical records were reviewed for demographic information, pathologic findings, treatment regimens and outcomes. Results: Median age at diagnosis was 30 years (range 5-46). All patients underwent surgery with unilateral salpingo-oophorectomy performed in 26 patients (55%), and hysterectomy with bilateral salpingo-oophorectomy in 21 patients (45%). Sixteen patients (34.0%) had stage I disease, six (12.8%) stage II, 23 (48.9%) stage III, and two patients (4.3%) had stage IV disease. Information on adjuvant treatment was available for 43 patients: 83.3% received chemotherapy alone, 9.5% chemotherapy followed by radiotherapy, 2.4% chemoradiation, and 4.8% did not receive any adjuvant therapy. Median follow-up was 13.2 months with a median overall survival of 14.9 months. Multi-agent chemotherapy and radiotherapy were associated with a better prognosis. On multivariate analysis, factors associated with favorable prognosis included absence of large cell component (p = 0.0003, HR = 0.19, 95% CI 0.08 to 0.47) and early stage disease (p=0.0029, HR=0.28, 95% CI 0.12 to 0.64). Median overall survival (OS) for the 12 patients with a large cell component was 8.8 months compared with 19.4 months for the 35 patients without a large cell component. Median OS for patients with early stage disease was 35.3 months compared with 10.4 months for patients with advanced stage disease. A better prognosis was also associated with the use of radiotherapy (p = 0.0365, HR = 0.26, 95% CI 0.07 to 0.92). The multiagent chemotherapy regimen of vinblastine, cisplatin, cyclophosphamide, bleomycin, doxorubicin and etoposide (VPCBAE) was associated with a decreased rate of recurrence (p = 0.0394). Conclusion: These findings shows a predominant incidence in young adults, caucasian, with large. Frequent misinterpreted as other ovarian neoplasms. Surgery was part of the initial treatment of all patients followed by complementary platinum- based chemotherapy for most patients. High recurrence rates despite treatments. Favorable prognostic factors included absence of large cell component, early stage disease, use of radiotherapy and chemotherapy with VPCBAE regimen. Further study is needed to improve outcomes in these patients including the adoption of systemic therapies used in MRT as well as the development of novel agents targeting specific mutations.